Company Interview / Lumos testing billion dollar market

Key points:

Lumos Diagnostics (ASX: LDX) CEO Doug Ward outlines FebriDx as a first-in-class bacterial vs viral respiratory test for US point-of-care settingsUS market for respiratory point-of-care consultations estimated at 80 million patients annuallyExclusive US distribution deal with Phase Scientific targeted to deliver US$317m over six yearsManufacturing scale-up and contract work, including with Hologic, seen as additional growth drivers

Lumos Diagnostics targets US$1bn respiratory testing opportunity with FDA clearance, CEO Doug Ward states that US regulatory clearance for its FebriDx respiratory diagnostic is a transformational step for the company. Ward says the FDA 510(k) and CLIA waiver mean FebriDx can now be marketed in US primary care and urgent care settings, where around 80 million respiratory patients are seen each year. The test is described as the first of its class aiming to help clinicians distinguish bacterial from viral infections at the point of care, potentially guiding more appropriate antibiotic use.

Ward outlines a market opportunity he estimates at about US$1 billion and argues it could take Lumos from about US$12 million in revenue to an US$80–100 million product line over the next five to six years. He highlights an exclusive US distribution deal with Phase Scientific, which Ward says commits to at least US$317 million in revenue to Lumos over six years, with commercial rollout beginning immediately.

Beyond FebriDx, Ward points to manufacturing scale-up over the next 12–24 months and a growing contract services business. He notes ongoing work with Hologic on next‑generation diagnostics and suggests sustained revenue and earnings growth are key to recovering Lumos’ share price (ASX:LDX).